Reduced levels of VEGF have been reported in AD patients while decreased levels of VEGF may contribute to neurodegenerative diseases such as Parkinson’s and multiple sclerosis (MS) through affecting neuronal plasticity and survival [196, 202] [203]. This evidence concerns the gene VEGFA and myeloid sarcoma.